Replimune stock was down 76.88% in pre-market trading on Tuesday, following a 1.94% rally yesterday. The company’s shares ...

Replimune stock cratered Tuesday after the Food and Drug Administration unexpectedly rejected its experimental melanoma ...

Replimune Group, Inc. faces FDA setbacks with RP1, raising financial risks and dilution concerns. Click here to find out why ...

The FDA has rejected Replimune’s request for approval of RP1, adding the melanoma drug candidate to the list of assets to ...

Replimune (REPL) stock in focus as the FDA rejects its lead drug RP1 as part of a combination regimen for melanoma, a type of ...

Replimune Group (NASDAQ:REPL – Get Free Report) ‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a note issued to investors on Thursday,Benzinga reports ...

J.P. Morgan analyst Anupam Rama maintained a Buy rating on AnaptysBio today and set a price target of $80.00. The company’s shares opened today at $28.15. Take advantage of TipRanks Premium at 50% off ...

Investing.com -- Replimune Group, Inc. (NASDAQ: REPL) stock plunged 77% after the company announced it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) ...